Last Updated: Wednesday, August 13, 2014, 20:11
India's top 20 pharmaceutical companies would increase capital expenditure by 40 percent to more than Rs 50,000 crore by fiscal 2018, credit rating agency CRISIL said Wednesday.
Last Updated: Monday, July 21, 2014, 13:33
The combination of Sun Pharma and Ranbaxy creates the fifth-largest speciality generics company in the world and the largest pharmaceutical company in India.
Last Updated: Sunday, July 20, 2014, 12:42
Among MNCs, Sanofi Aventis, Abbott and Pfizer are also likely to be affected owing to their sizeable share exposure on anti-diabetic segment and Indian market in general.
Last Updated: Thursday, June 26, 2014, 13:28
This was in order to maintain their market share and destroy competition, the Coalition for Affordable Care said in a media statement.
Last Updated: Wednesday, June 04, 2014, 14:10
Glenmark Pharmaceuticals on Thursday opened a new manufacturing facility in Switzerland for supply of clinical trial material.
Last Updated: Saturday, May 24, 2014, 15:01
The Andhra Pradesh High Court vacated a status quo order it had issued earlier on Sun Pharma-Ranbaxy merger process.
Last Updated: Tuesday, May 13, 2014, 19:47
The government on Tuesday cleared private equity major KKR's proposal to acquire stakes in two pharmaceutical companies in deals worth over Rs 1,400 crore, including 38 percent stake buy in Gland Pharma.
Last Updated: Tuesday, May 06, 2014, 19:32
Problems faced by Indian drug makers in the US are not related with quality but more due to documentation and data maintenance, a senior government official said Tuesday.
Last Updated: Thursday, April 24, 2014, 16:38
India's pharmaceutical exports registered slowest growth in at least 15 years at 1.2 percent to USD 14.84 billion last fiscal amid growing tension with the US over intellectual property rights related issues.
Last Updated: Monday, April 21, 2014, 22:10
India allows 100 percent FDI in pharma sector.
Last Updated: Saturday, February 15, 2014, 09:54
American pharma companies and their advocacy groups on Friday rued at the alleged restrictive India policies on clinical research, saying such policies are harming the companies.
Last Updated: Sunday, January 12, 2014, 15:05
BoAML said it sees strong base business growth at Sun, Dr Reddy, Lupin and Aurobindo Pharma.
more videos >>